timothy sykes logo
ALNY Stock Rebounds As Analysts Back RNAi Momentum Thumbnail
G Google News

ALNY Stock Rebounds As Analysts Back RNAi Momentum

TIM SYKES•UPDATED SEP. 2, 2026, 3:02 PM ET
Reviewed by Bryce Tuoheyand Fact-checked by Matt Monaco

Alnylam Pharmaceuticals Inc. stocks have been trading up by 8.51 percent after strong RNAi pipeline and partnership updates boosted optimism.

Key Takeaways

  • Wall Street desks leaned back into ALNY after Q2 guidance disappointment, with several firms calling the pullback an opportunity rather than a breakdown in the story.
  • BMO and Raymond James highlighted Alnylam’s ATTR and RNAi pipeline strength, setting aggressive price targets well above where ALNY has been trading recently.
  • Reduced 2026 TTR guidance knocked sentiment, but H.C. Wainwright and Barclays still project large upside if execution on Amvuttra and other assets improves.
  • Fresh ESC 2026 data for AMVUTTRA, patisiran, and zilebesiran reinforced Alnylam’s cardiovascular RNAi franchise and helped ease event risk around key trials.
  • A U.S. Department of Veterans Affairs contract worth up to $387.84M added another layer of revenue visibility for ALNY’s long-term growth path.

Candlestick Chart

Live Update At 15:02:27 EDT: On Wednesday, September 02, 2026 Alnylam Pharmaceuticals Inc. stock [NASDAQ: ALNY] is trending up by 8.51%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

ALNY has quietly staged a sharp recovery on the chart. From a close near $217 in mid-August 2026 to about $267 on 2026/09/02, Alnylam traders have seen a roughly 23% rebound in just a few weeks. That kind of bounce, off a steep prior slide, is pure momentum fuel for active trading.

The daily candles show a steady grind higher, with ALNY posting a series of higher lows from the $220s into the $260s. Intraday on 2026/09/02, ALNY opened near $246, ripped toward $269 by late morning, then consolidated in a tight $264–$267 band into the close. That’s classic “trend day” action, where dips keep getting bought and volatility compresses near the highs.

More Breaking News

Under the hood, Alnylam is a high-margin RNAi platform play. The company posted about $3.71B in trailing revenue, with a hefty 92.1% gross margin and positive EBIT margin of 23.4%. Yet ALNY still carries a rich 40.9x P/E and 6.7x price-to-sales, so traders are clearly paying up for growth. With a current ratio of 3.1 and free cash flow around $292M last quarter, the balance sheet looks sturdy enough to support ongoing R&D-heavy growth. For short-term traders, this combination of strong fundamentals and renewed price strength is why ALNY stays on screens.

Why Traders Are Watching ALNY Right Now

The story around ALNY flipped from fear to opportunity once the sell side stepped back in. After Alnylam cut its 2026 transthyretin (TTR) product revenue guidance by about $200M and the stock slid hard, many assumed the RNAi leader had lost its edge. Then the analyst cluster emerged.

BMO Capital kicked off with an Outperform on ALNY and a $318 target, framing the post-guidance drop as an attractive entry tied to the strength of the ATTR franchise and deep RNAi pipeline. For traders, that matters. It tells you big-money clients are being told the weakness is more reset than rupture.

Raymond James went further, upgrading Alnylam to Strong Buy while holding a $420 target. The firm argued that, after roughly a 35% slide since early July, ALNY was trading as if a bear-case on the TTR business was already baked in, with almost no value credited to the broader pipeline. That is exactly the sort of asymmetric risk/reward traders hunt: ugly recent chart, but analysts saying downside is largely priced.

Even the more cautious calls still lean positive. H.C. Wainwright trimmed its ALNY target to $455 from $485 after the guidance cut, yet still talked about more than 100% upside from the post-drop levels. Barclays lowered its target to $450 from $527 but kept an Overweight rating and framed the selloff as overdone, noting Amvuttra’s ramp should track prescriber expansion.

On the clinical side, ESC Congress 2026 turned into a key catalyst. ALNY delivered new data showing vutrisiran (AMVUTTRA) and patisiran generated consistent benefits in ATTR-CM and hATTR-PN, including patients already on tafamidis. For traders, that screams market expansion, not contraction. Phase 2 subgroup results for zilebesiran supported a move into Phase 3 for uncontrolled hypertension, while an ongoing ZENITH outcomes trial signaled Alnylam is pushing beyond rare disease into broad cardiovascular territory.

Oppenheimer added another layer, saying fresh ALNY data boosted conviction in Nucresiran and the TRITON-CM trial, reiterating an Outperform with a $350 target versus a roughly $240 share price at the time. Tie that to the roughly $387.84M VA contract win, and traders see a blend of pipeline de-risking plus real-world revenue.

Conclusion

For active traders, ALNY right now is a classic high-volatility, high-conviction biotech setup. The stock cratered after the 2026 TTR guidance reset, then bounced hard as clinical data and analyst calls started clearing the fog. Alnylam’s ESC 2026 updates around AMVUTTRA, patisiran, and zilebesiran did more than just pad slide decks — they helped rebuild confidence that the ATTR and cardiovascular RNAi franchises still have long legs.

On the numbers side, Alnylam’s 92.1% gross margin, strong EBIT margin, and solid cash generation give ALNY real staying power, even with a premium P/E and price-to-sales multiple. The balance sheet carries leverage, but with a current ratio over 3 and nearly $3.31B in cash and short-term investments, the company has room to keep funding late-stage programs. For short-term trading, that reduces the tail risk of sudden dilution or a liquidity crunch.

Layer in the outsized price targets — from BMO’s $318 to Oppenheimer’s $350, Barclays’ $450, H.C. Wainwright’s $455, and Raymond James at $420 — and traders see a wide band of potential upside from current ALNY levels if execution stays on track. The $387.84M VA contract adds incremental support.

Traders in the Tim Sykes world tend to respect one core idea: catalyst plus chart is where the edge lives. Tim often reminds students, “Patterns repeat because human nature doesn’t change — your job is to recognize them and manage risk like a pro.” As millionaire penny stock trader and teacher Tim Sykes, says, “It’s not about how much money you make; it’s about how much money you keep.”. ALNY is a live case study in that mindset — a heavy selloff, followed by improving news flow, analyst upgrades, and a grinding uptrend that disciplined traders can study, stalk, and, if it fits their plan, trade around. This coverage is for educational and research purposes only, but ALNY is a ticker worth watching closely.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”